ALLO – Allogene Therapeutics, Inc.
Float Short %
12.59
Margin Of Safety %
Put/Call OI Ratio
0.33
EPS Next Q Diff
-0.02
EPS Last/This Y
0.38
EPS This/Next Y
0.05
Price
2.06
Target Price
7.38
Analyst Recom
1.47
Performance Q
56.49
Upside
-721.5%
Beta
0.56
Ticker: ALLO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | ALLO | 1.715 | 0.12 | 0.04 | 5958 |
| 2026-01-26 | ALLO | 1.515 | 0.10 | 2.76 | 7621 |
| 2026-01-27 | ALLO | 1.525 | 0.24 | 0.37 | 8809 |
| 2026-01-28 | ALLO | 1.455 | 0.24 | 7.14 | 8843 |
| 2026-01-29 | ALLO | 1.585 | 0.28 | 0.35 | 9169 |
| 2026-01-30 | ALLO | 1.835 | 0.28 | 0.31 | 9184 |
| 2026-02-02 | ALLO | 1.87 | 0.28 | 0.15 | 9183 |
| 2026-02-03 | ALLO | 1.73 | 0.28 | 0.02 | 9209 |
| 2026-02-04 | ALLO | 1.805 | 0.28 | 0.08 | 9094 |
| 2026-02-05 | ALLO | 1.635 | 0.28 | 0.04 | 9120 |
| 2026-02-06 | ALLO | 1.695 | 0.28 | 0.61 | 9082 |
| 2026-02-09 | ALLO | 1.695 | 0.29 | 0.19 | 9115 |
| 2026-02-10 | ALLO | 1.7 | 0.29 | 0.06 | 9190 |
| 2026-02-11 | ALLO | 1.665 | 0.28 | 0.22 | 9287 |
| 2026-02-12 | ALLO | 1.625 | 0.28 | 0.19 | 9278 |
| 2026-02-13 | ALLO | 1.81 | 0.28 | 0.10 | 9252 |
| 2026-02-17 | ALLO | 2.16 | 0.27 | 0.44 | 9556 |
| 2026-02-18 | ALLO | 2.265 | 0.35 | 0.03 | 11249 |
| 2026-02-19 | ALLO | 2.14 | 0.35 | 0.04 | 11515 |
| 2026-02-20 | ALLO | 2.06 | 0.33 | 0.02 | 11869 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | ALLO | 1.72 | 21.7 | - | -0.94 |
| 2026-01-26 | ALLO | 1.52 | 21.7 | - | -0.94 |
| 2026-01-27 | ALLO | 1.52 | 21.7 | - | -0.94 |
| 2026-01-28 | ALLO | 1.45 | 21.7 | - | -0.94 |
| 2026-01-29 | ALLO | 1.59 | 21.7 | - | -0.94 |
| 2026-01-30 | ALLO | 1.84 | 21.7 | - | -0.94 |
| 2026-02-02 | ALLO | 1.88 | 21.7 | - | -0.94 |
| 2026-02-03 | ALLO | 1.74 | 21.7 | - | -0.94 |
| 2026-02-04 | ALLO | 1.80 | 21.7 | - | -0.94 |
| 2026-02-05 | ALLO | 1.63 | 21.7 | - | -0.94 |
| 2026-02-06 | ALLO | 1.70 | 21.7 | - | -0.94 |
| 2026-02-09 | ALLO | 1.70 | 21.7 | - | -0.94 |
| 2026-02-10 | ALLO | 1.70 | 21.7 | - | -0.94 |
| 2026-02-11 | ALLO | 1.66 | 21.7 | - | -0.94 |
| 2026-02-12 | ALLO | 1.63 | 21.7 | - | -0.94 |
| 2026-02-13 | ALLO | 1.81 | 21.7 | - | -0.94 |
| 2026-02-17 | ALLO | 2.15 | 21.7 | - | -0.94 |
| 2026-02-18 | ALLO | 2.27 | 21.7 | - | -0.94 |
| 2026-02-19 | ALLO | 2.14 | 21.7 | - | -0.94 |
| 2026-02-20 | ALLO | 2.06 | 21.7 | - | -0.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | ALLO | -0.10 | -7.73 | 11.28 |
| 2026-01-26 | ALLO | -0.10 | -7.82 | 11.28 |
| 2026-01-27 | ALLO | -0.10 | -7.82 | 11.28 |
| 2026-01-28 | ALLO | -0.10 | -7.82 | 11.63 |
| 2026-01-29 | ALLO | -0.10 | -7.82 | 11.67 |
| 2026-01-30 | ALLO | -0.10 | -7.82 | 11.67 |
| 2026-02-02 | ALLO | -0.10 | -7.90 | 11.67 |
| 2026-02-03 | ALLO | -0.10 | -7.90 | 11.67 |
| 2026-02-04 | ALLO | -0.38 | -7.90 | 11.67 |
| 2026-02-05 | ALLO | -0.39 | -7.90 | 11.67 |
| 2026-02-06 | ALLO | -0.39 | -7.90 | 11.67 |
| 2026-02-09 | ALLO | -0.39 | -9.41 | 12.10 |
| 2026-02-10 | ALLO | -0.36 | -9.41 | 12.10 |
| 2026-02-11 | ALLO | -0.36 | -9.41 | 12.22 |
| 2026-02-12 | ALLO | -0.36 | -9.41 | 12.22 |
| 2026-02-13 | ALLO | -0.36 | -9.41 | 12.22 |
| 2026-02-17 | ALLO | -0.36 | 1.91 | 12.38 |
| 2026-02-18 | ALLO | -0.35 | 1.91 | 12.38 |
| 2026-02-19 | ALLO | -0.35 | 1.91 | 12.38 |
| 2026-02-20 | ALLO | -0.35 | 1.91 | 12.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.22
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
-0.35
Institutional Transactions
1.91
Beta
0.56
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
22
Sentiment Score
94
Actual DrawDown %
94.7
Max Drawdown 5-Year %
-97.6
Target Price
7.38
P/E
Forward P/E
PEG
P/S
P/B
1.45
P/Free Cash Flow
EPS
-0.98
Average EPS Est. Cur. Y
-0.94
EPS Next Y. (Est.)
-0.89
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.91
Return on Equity vs Sector %
-96.2
Return on Equity vs Industry %
-78.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.09
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading